47
Participants
Start Date
April 25, 2023
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2025
GFH925
GFH925 tablets administered orally daily.
Cetuximab
Cetuximab administered intravenously Q2W.
Clinica Mi Tres Torres, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Candiolo Cancer Institute, FPO-IRCCS, Candiolo
"University General Hospital Attikon", Athens
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Hospital Regional Universitario de Malaga,Oncology Dept, Málaga
Clinica Universidad de Navarra, Servicio de Oncologia, Pamplona
IRCCS Centro di Riferimento Oncologico, Aviano
IOV - Istituto Oncologico Veneto IRCCS, Padova
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma), Verona
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna
Virgen del Rocio University Hospital, Seville
Instituto Valenciano de Oncologia IVO,Servicio de Oncologia Medica, Valencia
A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena
"General Hospital of Athens Alexandra", Athens
"University General Hospital Attikon", Athens
Bioclinic Thessaloniki, Thessaloniki
Istituto Nazionale Tumori Regina Elena IRCCS, Rome
ICO Badalona - Hospital Universitari Germans Trias i Pujol,Servicio de Oncologia Medica, Badalona
Hospital Universitari Dexeus,Servicio de Oncologia Medica, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Genfleet Therapeutics (Shanghai) Inc.
INDUSTRY